RT Journal Article
SR Electronic
T1 TRAIL-engineered Bone Marrow-derived Mesenchymal Stem Cells: TRAIL Expression and Cytotoxic Effects on C6 Glioma Cells
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 729
OP 734
VO 34
IS 2
A1 XIANG-JUN TANG
A1 JUN-TI LU
A1 HAN-JUN TU
A1 KUAN-MING HUANG
A1 RUI FU
A1 GANG CAO
A1 MIN HUANG
A1 LONG-HAI CHENG
A1 LONG-JUN DAI
A1 LI ZHANG
YR 2014
UL http://ar.iiarjournals.org/content/34/2/729.abstract
AB Background: TNF-related apoptosis-inducing ligand (TRAIL) is considered as a tumor cell-specific cytotoxic agent. Through the aid of mesenchymal stem cells (MSCs), TRAIL is capable of inducing apoptosis of tumor cells in tumor sites. The present study was performed to investigate the cytotoxic effects of TRAIL-engineered MSCs on glioblastoma cells (C6) in vitro. Materials and Methods: An expression vector of secreting form of TRAIL was used to engineer MSCs. The cytotoxic effects of TRAIL-transfected MSCs on C6 cells were invstigated using the MTT method and Hochest33258 staining after co-culture of the two cell types. Results: TRAIL and control plasmid transfection of MSCs showed no significant effect on MSC's viability (p>0.05). A significant inhibition of C6 cells was observed when they were co-cultured with TRAIL-engineered MSCs (63.7%±0.12, p<0.05). Conclusion: Mesenchymal stem cells were very well tolerant to the transfection of TRAIL-bearing vectors. The cytotoxic effects of TRAIL-engineered MSCs on C6 cells indicates the therapeutic potential of this strategy for treatment of glioblastoma patients.